Treatment Results
Sonablate: Oncological outcomes according to different generations of devices

Courtesy of V.Mouraviev MD, PhD
Sonablate: Intermediate- and long-term oncological outcomes according to risk disease and device of different generations
Sonablate: Intermediate- and Long-term oncological outcomes according to risk disease and device of different generations
What is HIFU?
For a Free Consultation or Second Opinion, please fill out the form below!
This information will only be used to provide you with information about HIFU. Your information will not be shared.
Total: 753 pts with up to 12 years follow-up
BDFS criteria: Phoenix
Best outcome in low- and moderate risk categories
Courtesy of V.Mouraviev MD, PhD
Ablatherm HIFU
(Green is treated, Red is being treated)

Ablatherm: Long-Term Oncological outcomes
Results of Primary HIFU Treatment using Ablatherm
MFS=Metastasis Free Survival
CSS=Cancer Specific Survival
Ganzer et al., BJUI, 2013
Results of HIFU Treatment for
Localized Prostate Cancer with 15 year followup
Patients with T1 T2 N0 M0 PSA less than 50 were treated. No patient had Androgen therapy for T3 disease. All patients were treated with Ablatherm HIFu machine. Phoenix definition was used for biochemical failure. 704 patients studied, 78.5% had intermediate or high risk disease. Mean follow up was 5.3 years (range 1.3 to 14). Cancer specific survival was 99%, metastatic free survival was 95%.
10 year treatment free rates were 98% in low, 72% in intermediate and 68% in high risk. 15% of patients had second treatment with HIFU.

Ablatherm: 10-year oncological result
References:
Ganzer R, BJU Int.2013 Aug; 112 (3): 322-9; Thuroff S, Chaussy C: J Urol.2013
Aug; 190 (2): 702-10; Crouzet S Eur Urol.2014 May; 65 (5): 907-14
Outcomes of Radical Surgery
Comparison of Surgery and HIFU
Radical Prostatectomy Outcomes at 10 years Compared to HIFU
Outcomes of Radiation
Radiation Therapy Outcomes at 5 and 10 Years
Radiation Therapy Outcomes at 5 and 10 Years
Radiation Therapy Outcomes at 5 and 10 Years
Comparison of HIFU and Radiation
Outcomes of Primary HIFU Treatment using Ablatherm Compared to Radiation
Reference: Ganzer et al, BJUI, 2013, Crouzet et al, AUA, 2013, Thuroff & Chaussey, JU, 2013, Zelefsky 2011, Zietman 2010, Jones 2011
Side effects/Complications of various Treatments of Prostate Cancer
HIFU (Ablatherm) Complications
HIFU (Sonablate) Complications
Surgery Complications
Surgery Short Term Complications
Radiotherapy Complications
HIFU Long Term Complications
Surgery Long Term Complications
Radiotherapy Long Term Complications
Comparison between Ablatherm and Sonablate Complications
1. Ganzer R et al BJU Int. 2013 Aug; 112(3):322-9
2. Crouzet S et al Eur Urol. 2014 May;65(5):907-14
3. Uchida T et al J Urol. 2015 Jan; 193(1):103-10
4. Dickinson L et al Eur Urol 2016
5. FDA Presentation Ablatherm 2014
6. Ahmed HU et al Br J Cancer. 2009 Jul 7;101(1):19-26
7. Pascal R et al Presented at the 2016 AUA San Diego, CA
8. Ahmed HU et al Eur Urol. 2015 Dec;68(6):927-36
9. Ahmed HU et al Lancet Oncol. 2012 Jun;13(6):622-32
10. van Velthoven R et al Prostate Cancer Prostatic Dis. 2016 Mar;19(1):79-83
11. Feijoo ER et al Eur Urol. 2016 Feb; 69(2):214-20
12. Guillaumier et al Presented at the 2016 AUA San Diego, CA
13. Crouzet et al Radiother Oncol. 2012 Nov;105(2):198-202
14. Ahmed HU et al Cancer. 2012 Jun 15;118(12):3071-8
15. Uchida T et al BJU Int. 2011 Feb; 107(3):378-82
16. FDA Presentation Sonacare 2014